The Immune Report Card Assay uses five different testing methodologies (IHC, FISH, MSI, mutational burden, NGS sequencing) with the results consolidated into one summary report.
88360-TC, 88360-26, 81301, 88342, 88377, 81455 (81479 for Medicare), 88381
Different cancer types
Non-Small-Cell Lung Cancer (NSCLC)
FFPE tissue block preferred. Unstained slides accepted.
Block is preferred, or send 15 unbaked, positively charged, unstained slides cut at 5 µm.
If submitting a sample for both the OmniSeq Immune Report Card and OmniSeq Comprehensive Assay, submit 20 unbaked, positively charged, unstained slides cut at 5 µm.
Primary tumor type and stage of disease required and needs to be included on the test requisition. Please include the pathology report when submitting a sample. If a pathology report is not received with the sample, testing will be delayed.
Causes for Rejection
Tumor block containing insufficient tumor; broken or stained slides; decalicified bone biopsies; cytology smears. Specimens with very small amounts of tumor and/or less than requested number of slides will be accepted with the caveat that complete testing may not be possible.
FFPE blocks are stored at room temperature and shipped with no special precautions, except when daily outside temperatures exceed 35°C, and then ship with cool packs to avoid paraffin meltdown.
The Immune Report Card assay includes PD-L1( FDA-approved), microsatellite instability (MSI), tumor mutational burden, and gene expression of 54 specific immune markers related to tumor infiltrating lymphocytes and T-cell receptor signaling.
The Immune Report Card assay measures multiple immune biomarkers present in DNA, RNA, proteins, and cells to comprehensively interrogate the cancer-immunity cycle. Single biomarker assays only evaluate one or two steps in the immune cycle and thus may miss the complete picture.